Health Catalyst (HCAT) Q3 2026 Earnings Call Transcript

Health Catalyst reported Q3 2026 revenue of $56.3 million, above its $55 million-$56 million guidance, and adjusted EBITDA of $779,000, above the $0-$500,000 range. The company reaffirmed 2026 revenue guidance of $246 million-$249 million and adjusted EBITDA guidance of $18 million-$18.5 million, while forecasting a Q4 adjusted EBITDA loss of $1.3 million-$1.8 million. Health Catalyst ended the quarter with $79 million in cash and no debt after retiring its credit facility, but management cited elevated churn and professional-services margin pressure, including $1.6 million in medical claims costs above expectations.

Analysis

The key distinction is between bookings momentum and revenue durability: bookings above target do not offset churn until they convert through implementation and renewals. That conversion lag leaves near-term reported growth exposed even if demand is healthy. The new CEO’s retention priority is therefore the central valuation catalyst, not the quarterly beat.

Underlying earnings quality remains fragile. Project Nexus savings are being partly absorbed by claims costs and team investment, while professional-services gross margin near breakeven signals a capacity-adjustment problem, not yet a demonstrated operating-model reset. Q4’s loss should not be annualized mechanically because it includes the first full quarter without Vitalware and seasonal claims, but it does expose the lower post-divestiture earnings base. The divestiture gain makes GAAP net income a poor indicator of recurring profitability.

Over 1–3 months, watch renewal/churn commentary, bookings conversion, and services cost alignment; over 6–18 months, the thesis depends on migration-related churn actually easing by the stated 2027 timeframe. Ending a loss-making HIE relationship may improve economics, but could also reduce interoperability value for some clients and complicate retention. The debt-free balance sheet lowers financing risk, but does not solve revenue leakage. With no valuation or share-price context supplied, the signal supports caution rather than an unconditional short.

Key Decisions for Investors

• Do not treat the quarterly EBITDA beat or GAAP profit as evidence of a durable earnings inflection; keep HCAT at watchlist/neutral sizing until renewal retention and post-migration revenue stabilize.
• For a tactical bearish expression, consider a defined-risk HCAT put spread only if the stock rallies while management provides no measurable improvement in churn or services margins; avoid an outright short absent valuation and borrow data.
• Reassess after the next results: look for churn pressure to moderate, bookings to convert into recognized revenue, and professional-services margin to recover as delivery costs reset. Failure on these measures would strengthen the downside case.
• Falsifiers: sustained improvement in client retention and technology revenue, bookings converting without offsetting churn, and services-margin recovery would weaken the cautious thesis; worsening migration churn or further guidance reductions would reinforce it.